We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.11B
1-Year Est. Return 171.34%
This Fund
S&P 500
This Quarter Est. Return
-18.48%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$1.03B
AUM Growth
-$231M
Cap. Flow
+$83.3M
Cap. Flow %
8.09%
Top 10 Hldgs %
74.22%
Holding
35
New
1
Increased
3
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$62.2M
2
TSVT
2seventy bio
TSVT
+$20.9M
3
MRSN
Mersana Therapeutics
MRSN
+$5.31M
4
XFOR icon
X4 Pharmaceuticals
XFOR
+$254K

Top Sells

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$5.38M

Sector Composition

Rank Sector Weight
1 Healthcare 94.71%
2 Financials 3.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARYD
26
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$6.86M 0.67%
700,000
– –
SYRE icon
27
Spyre Therapeutics
SYRE
$9.18B
$6.55M 0.64%
113,908
– –
XFOR icon
28
X4 Pharmaceuticals
XFOR
$425M
$5.28M 0.51%
100,651
+4,433
+5% +$254K
PANA
29
DELISTED
Panacea Acquisition Corp. II Class A Ordinary Shares
PANA
$4.88M 0.47%
500,000
– –
ARYE
30
DELISTED
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
$4.86M 0.47%
500,000
– –
BLSA
31
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$4.81M 0.47%
487,500
– –
OMEG
32
DELISTED
Omega Alpha SPAC Class A Ordinary Shares
OMEG
$3.93M 0.38%
400,000
– –
FLACU
33
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
$3M 0.29%
300,000
– –
JYAC
34
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$2.95M 0.29%
300,000
– –
BLUE
35
DELISTED
bluebird bio
BLUE
– –
-26,909
Closed -$5.38M
1
2

Similar funds

JTWM
Jackson Thornton Wealth Management Montgomery, Alabama $1.11B AUM 22.53% 1-Year Est. Return
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
AIM
Advyzon Investment Management Lisle, Illinois $1.12B AUM 22.08% 1-Year Est. Return
MTCM
Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 18.84% 1-Year Est. Return
CNC
Canandaigua National Corp Canandaigua, New York $1.12B AUM

Bain Capital Life Sciences Investors's Q1 2022 Portfolio in Review

As of Q1 2022, Bain Capital Life Sciences Investors held 35 positions worth $1.03B, down 18% from $1.26B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Bain Capital Life Sciences Investors deployed $83.3M of net new capital in Q1 2022, opening 1 new position and adding to 3 existing holdings. Its largest new stake was Amylyx Pharmaceuticals: 2,756,050 shares worth $35.4M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 95% a quarter earlier, followed by Financials.

On the sell side, the most notable exit was bluebird bio, an estimated $5.38M sold.

  • Bain Capital Life Sciences Investors's largest Q1 2022 buy was Amylyx Pharmaceuticals: 2,756,050 shares worth $35.4M.
  • Bain Capital Life Sciences Investors added most to 2seventy bio in Q1 2022, an estimated $20.9M increase.
  • Bain Capital Life Sciences Investors fully exited bluebird bio in Q1 2022, selling an estimated $5.38M.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 74% of its $1.03B portfolio in Q1 2022.
  • Bain Capital Life Sciences Investors opened 1 new position and closed 1 in Q1 2022.
  • Bain Capital Life Sciences Investors's portfolio value fell 18% quarter-over-quarter to $1.03B.

Based on Bain Capital Life Sciences Investors's 13F filing for Q1 2022, filed 16 May 2022.